Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

Cancer Cell

Volumn 24, Issue 5, 2013, Pages 589-602

  Klug, Felix ^a   Prakash, Hridayesh ^a,b,c   Huber, Peter E ^b   Seibel, Tobias ^a   Bender, Noemi ^a   Halama, Niels ^b   Pfirschke, Christina ^a   Voss, RalfHolger ^d   Timke, Carmen ^b   Umansky, Ludmila ^a   Klapproth, Kay ^a   Schäkel, Knut ^b   Garbi, Natalio ^a,e   Jäger, Dirk ^b   Weitz, Jürgen ^b   Schmitz Winnenthal, Hubertus ^b   Hämmerling, Günter J ^a   Beckhove, Philipp ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF HYDERABAD   (India)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CHEMOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; GAMMA IRRADIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 84887561907     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.09.014     Document Type: Article

References (38)

1. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167:195-205.
2. Antonia S., Mulé J.J., Weber J.S. Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 2004, 16:130-136.
3. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and Tcell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
4. Cao Z.A., Daniel D., Hanahan D. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002, 2:11.
5. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., Braga M., Di Carlo V., Doglioni C., Protti M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J.Exp. Med. 2011, 208:469-478.
6. Domschke C., Schuetz F., Ge Y., Seibel T., Falk C., Brors B., Vlodavsky I., Sommerfeldt N., Sinn H.P., Kühnle M.C., et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 2009, 69:8420-8428.
7. Feuerer M., Beckhove P., Garbi N., Mahnke Y., Limmer A., Hommel M., Hammerling G.J., Kyewski B., Hamann A., Umansky V., Schirrmacher V. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat. Med. 2003, 9:1151-1157.
8. Fridman W.H., Galon J., Pagès F., Tartour E., Sautès-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011, 71:5601-5605.
9. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
10. Ganss R., Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 1998, 58:4673-4681.
11. Ganss R., Ryschich E., Klar E., Arnold B., Hämmerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002, 62:1462-1470.
12. Garbi N., Arnold B., Gordon S., Hämmerling G.J., Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J.Immunol. 2004, 172:5861-5869.
13. Garvey E.P., Oplinger J.A., Furfine E.S., Kiff R.J., Laszlo F., Whittle B.J., Knowles R.G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase invitro and invivo. J.Biol. Chem. 1997, 272:4959-4963.
14. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
15. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
16. Griffioen A.W., Damen C.A., Blijham G.H., Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996, 88:667-673.
17. Halama N., Michel S., Kloor M., Zoernig I., Benner A., Spille A., Pommerencke T., von Knebel D.M., Folprecht G., Luber B., et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011, 71:5670-5677.
18. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Gröne H.J., Hämmerling G.J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
19. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
20. Hyduk S.J., Cybulsky M.I. Role of alpha4beta1 integrins in chemokine- induced monocyte arrest under conditions of shear stress. Microcirculation 2009, 16:17-30.
21. Islam S.A., Luster A.D. T cell homing to epithelial barriers in allergic disease. Nat. Med. 2012, 18:705-715.
22. Johansson A., Hamzah J., Payne C.J., Ganss R. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl. Acad. Sci. USA 2012, 109:7841-7846.
23. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
24. Marley S.B., Hadley C.L., Wakelin D. Genetic variation in neutrophil accumulation in mice is not mediated through immigrant regulatory cells. Clin. Exp. Immunol. 1995, 102:224-228.
25. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11:702-711.
26. Multhoff G., Molls M., Radons J. Chronic inflammation in cancer development. Front. Immunol. 2011, 2:98.
27. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
28. + CD25+ regulatory Tcell infiltration of human pancreatic carcinoma. J.Natl Cancer Inst. 2007, 99:1188-1199.
29. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
30. Ryschich E., Schmidt J., Hammerling G.J., Klar E., Ganss R. Transformation of the microvascular system during multistage tumorigenesis. Int. J Cancer 2002, 97:719-725.
31. Schmitz-Winnenthal F.H., Volk C., Z'graggen K., Galindo L., Nummer D., Ziouta Y., Bucur M., Weitz J., Schirrmacher V., Büchler M.W., Beckhove P. High frequencies of functional tumor-reactive Tcells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005, 65:10079-10087.
32. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
33. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
34. Sutterwala F.S., Noel G.J., Salgame P., Mosser D.M. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J.Exp. Med. 1998, 188:217-222.
35. Tesniere A., Apetoh L., Ghiringhelli F., Joza N., Panaretakis T., Kepp O., Schlemmer F., Zitvogel L., Kroemer G. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 2008, 20:504-511.
36. Timke C., Winnenthal H.S., Klug F., Roeder F.F., Bonertz A., Reissfelder C., Rochet N., Koch M., Tjaden C., Buechler M.W., et al. Randomized controlled phase I/II study to investigate immune stimulatory effects by lowdose radiotherapy in primarily operable pancreatic cancer. BMC Cancer 2011, 11:134.
37. Voss R.H., Thomas S., Pfirschke C., Hauptrock B., Klobuch S., Kuball J., Grabowski M., Engel R., Guillaume P., Romero P., et al. Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human Tcells. Blood 2010, 115:5154-5163.
38. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjällman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95:272-281.